INTEGRA LIFESCIENCES HOLDINGS CORP — DEF 14A Filing
DEF 14A filed on April 6, 2026
🧾 What This Document Is
This is a Definitive Proxy Statement (DEF 14A) for Integra LifeSciences. It's an official invite and information packet sent to shareholders before the annual meeting. Its main jobs are to:
- Announce the annual shareholder meeting details.
- Provide information on the issues shareholders need to vote on.
- Give a transparent look at the company's governance, board members, and executive pay.
👉 Why it matters: Think of it as the company's "annual report card and agenda." It's where you learn who is running the show, how they are paid, and what big decisions you, as a shareholder, get to weigh in on.
🏢 What The Company Does
👉 In simple terms... Integra LifeSciences is a medical technology company that makes specialized products to help restore lives. They focus on critical areas like neurosurgery (brain and spine), wound care, and tissue repair. They sell these products in two main segments: Codman Specialty Surgical (think surgical tools and devices) and Tissue Technologies (skin substitutes and regenerative products).
The company is currently going through a major, multi-year transformation to fix past challenges with product quality and supply chain reliability, while trying to accelerate growth.
📅 The Annual Meeting
- When: Thursday, May 7, 2026, at 9:00 a.m. local time.
- Where: Company headquarters, 1100 Campus Road, Princeton, New Jersey 08540.
- Who Can Vote: Shareholders who owned stock as of the close of business on March 13, 2026.
🗳️ What Shareholders Are Voting On
The board recommends voting FOR all four proposals.
1. Elect Eight Directors (Page 8) You're voting to approve the eight people nominated to the board. More on them below.
2. Ratify the Auditor (Page 76) You're asked to approve PricewaterhouseCoopers LLP as the company's independent accounting firm for 2026. This is a standard check on the company's finances.
3. Advisory Vote on Executive Pay ("Say-on-Pay") (Page 79) This is a non-binding vote where shareholders can express their opinion on the compensation of the top executives. It's a way to hold management accountable.
4. Approve an Equity Plan Amendment (Page 80) You're voting to amend the company's stock award plan for employees. This is crucial for attracting and retaining talent by granting them stock options and shares.
👥 Who's on the Board? (Director Nominees)
The board is a mix of deep industry experience and fresh perspectives. Here’s a snapshot of the 8 nominees:
| Name & Age | Key Background & Why They're on the Board |
|---|---|
| Keith Bradley, 81 | Professor & strategy expert. Brings decades of board experience and international perspective. |
| Shaundra D. Clay, 55 | Former finance exec at Beam Suntory & Medtronic. Adds financial acumen and healthcare industry insight. |
| Stuart M. Essig, 64 (Chairman) | Former CEO of Integra. Deep company and industry knowledge. Transitioned from Executive Chairman back to Non-Executive Chairman in mid-2025. |
| Jeffrey A. Graves, 64 | CEO of 3D Systems. Adds operational leadership and tech/manufacturing expertise. |
| Barbara B. Hill, 73 | Healthcare ops partner at a private equity firm. Extensive healthcare leadership and board experience. Also the Presiding Director. |
| Renee W. Lo, 45 | VP at LinkedIn (APAC). Brings tech, digital transformation, and international business skills. Chairs the Compensation Committee. |
| Mojdeh Poul, 63 | Current President & CEO. Joined in Jan 2025. Over 30 years in med-tech leadership at 3M, Medtronic, and others. |
| Christian S. Schade, 65 | Former biotech CEO & finance executive. Brings financial, risk management, and life sciences industry expertise. Chairs Audit & Finance committees. |
👉 Notable Governance: The board is 50% women. All board committees (Audit, Compensation, Nominating) are made up entirely of independent directors.
💰 Executive Compensation Highlights
The pay philosophy is "pay-for-performance," meaning a large majority of executive pay is tied to hitting company goals.
Key Principles:
- Mix of Pay: Combination of salary, annual cash bonuses, and long-term stock awards.
- Performance-Linked: Bonuses and stock grants are based on hitting financial and strategic targets.
- Strong Governance: Includes clawback policies (they can take back pay if there's misconduct), no hedging or pledging company stock, and strict stock ownership rules for execs.
👉 Why it matters: This structure is designed to align the executives' interests with yours as a shareholder. They only get big payouts if the company does well.
🚀 The Big Picture: Transformation in Action
CEO Mojdeh Poul's message frames 2025 as a year of disciplined execution despite challenges. The company's performance highlights this tension:
-
👍 The Good:
- Revenue grew 1.5% to $1.64 billion.
- Made major progress on its "Compliance Master Plan" to fix quality issues.
- Relaunched key products (PriMatrix®, Durepair®) ahead of schedule.
- Launched new products like the Mayfield® Ghost Base Unit.
-
⚠️ The Challenges:
- Reported a GAAP Net Loss of $(516.5) million. This was largely due to big, upfront investments in fixing quality systems, upgrading facilities, and operational improvements.
- Tissue Technologies segment faced "product availability constraints."
The story here isn't just about one year's profit. It's about a company investing heavily to rebuild its foundation for sustainable future growth.
🔮 What's Next?
The company is pursuing a two-horizon plan that runs in parallel:
- Horizon 1 (The Foundation): Continue fixing quality, supply chain, and manufacturing. This is the heavy lifting to resolve FDA Warning Letters and build reliability.
- Horizon 2 (Acceleration): Use that solid foundation to speed up growth, innovation, and market leadership.
The goal for 2026 and beyond is to turn these foundational investments into stronger margins, better customer service, and profitable growth.
🧠 The Analogy
Integra is like a historic restaurant that's closed for a month to fix its kitchen, retrain its staff, and relaunch its classic dishes—all while keeping a few takeout windows open to pay the bills. The short-term cost is high (the net loss), and it’s inconvenient (supply constraints), but the goal is to come back stronger, with better service and quality, to win back customers for the long haul.
🧩 Final Takeaway
Integra LifeSciences is in the middle of a tough but necessary operational turnaround. The 2025 proxy shows a board and management team focused on fixing deep-seated quality and supply chain issues, even at the cost of short-term profits. As a shareholder, you're being asked to endorse the leadership team and their strategy, betting that these foundational investments will lead to a healthier, more profitable company in the future.